These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 797258

  • 1. A two-year crossover therapeutic trial with halofenate and clofibrate.
    Dujovne CA, Azarnoff DL, Pentikainen P, Manion C, Hurwitz A, Hassanein K.
    Am J Med Sci; 1976; 272(3):277-84. PubMed ID: 797258
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Halofenate in the treatment of type II hyperlipoproteinemia. Double blind comparison with clofibrate.
    Rees ED, Hamilton RD, Kanner IF, Wasson S, Hearn T.
    Atherosclerosis; 1976 Sep; 24(3):537-46. PubMed ID: 788722
    [Abstract] [Full Text] [Related]

  • 6. [Treatment of hyperlipemia and hyperuricemia with 2-acetamidoethyl-(4-chlorophenyl)-(3-trifluoromethylphenoxy)-acetate (halofenate), a derivative of clofibrate].
    Keller C, Wolfram G, Zöllner N.
    Arzneimittelforschung; 1976 Sep; 26(12):2221-4. PubMed ID: 798591
    [Abstract] [Full Text] [Related]

  • 7. The metabolic spectrum of halofenate.
    Ryan JR.
    Int J Clin Pharmacol Biopharm; 1975 Jul; 12(1-2):239-43. PubMed ID: 51838
    [Abstract] [Full Text] [Related]

  • 8. A one year double blind study of the effect of halofenate and clofibrate in patients with hyperlipoproteinemia.
    Rottiers R, van Egmond J.
    Acta Clin Belg; 1975 Jul; 30(5):398-408. PubMed ID: 1221746
    [No Abstract] [Full Text] [Related]

  • 9. Comparison of the effects of halofenate (MK-185) and clofibrate on plasma lipid and uric acid concentration in hyperlipoproteinemic patients.
    Lisch HJ, Patsch J, Sailer S, Braunsteiner H.
    Atherosclerosis; 1975 Jul; 21(3):391-9. PubMed ID: 1148032
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effects of halofenate and probenecid on serum lipids and uric acid in hyperlipidemic, hyperuricemic adults.
    Bassett DR, Mikkelsen WM, Buckingham RB, Block WD, Sidiq M, Shakibai A, DiGaetano R, Liou LL.
    Clin Pharmacol Ther; 1977 Sep; 22(3):340-51. PubMed ID: 330079
    [No Abstract] [Full Text] [Related]

  • 14. Efficacy and interactions of oxandrolone, halo-fenate and clofibrate in a factorial study on experimental acute nephrotic hyperlipidemia.
    Schapel GJ, Edwards KD.
    J Pharmacol Exp Ther; 1975 Jul; 194(1):274-84. PubMed ID: 1171221
    [Abstract] [Full Text] [Related]

  • 15. Potentiation of hypoglycemic effect of sulfonylureas by halofenate.
    Jain AK, Ryan JR, McMahon FG.
    N Engl J Med; 1975 Dec 18; 293(25):1283-6. PubMed ID: 171574
    [Abstract] [Full Text] [Related]

  • 16. Effect of halofenate on serum uric acid.
    Aronow WS, Harding PR, Khursheed M, Vangrow JS, Papageorge's NP.
    Clin Pharmacol Ther; 1973 Dec 18; 14(3):371-3. PubMed ID: 4572799
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Halofenate: effectiveness of two dosage forms and two dose schedules.
    Hutchison JC, Wilkinson WH.
    Atherosclerosis; 1974 Dec 18; 19(3):417-28. PubMed ID: 4133379
    [No Abstract] [Full Text] [Related]

  • 19. A comparative trial of clofibrate and nicotinyl alcohol tartrate in hyperlipoproteinemic patients.
    Dujovne CA, Azarnoff DL, Pentikainen P, Manion CV, Hurwitz A.
    Am J Med Sci; 1979 Dec 18; 277(3):255-61. PubMed ID: 222145
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.